Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice
Guangchun Jin, … , Arthur Shulkes, Timothy C. Wang
Guangchun Jin, … , Arthur Shulkes, Timothy C. Wang
Published August 3, 2009
Citation Information: J Clin Invest. 2009;119(9):2691-2701. https://doi.org/10.1172/JCI38918.
View: Text | PDF
Research Article Oncology

Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice

  • Text
  • PDF
Abstract

Hyperproliferation of the colonic epithelium, leading to expansion of colonic crypt progenitors, is a recognized risk factor for colorectal cancer. Overexpression of progastrin, a nonamidated and incompletely processed product of the gastrin gene, has been shown to induce colonic hyperproliferation and promote colorectal cancer in mice, but the mechanism of pathogenesis has not been defined. Cholecystokinin-2 receptor (CCK2R) is the primary receptor for cholecystokinin (CCK) and amidated gastrin. Here, we show that Cck2r was expressed in murine colonic crypts and upregulated in the transgenic mice that overexpress human progastrin. Murine deletion of Cck2r abrogated progastrin-dependent increases in colonic proliferation, mucosal thickness, and β-catenin and CD44 expression in the colon tumor. In addition, either deletion or antagonism of Cck2r resulted in the inhibition of progastrin-dependent increases in progenitors expressing doublecortin and CaM kinase–like-1 (DCAMKL1), stem cells expressing leucine rich repeat–containing G protein–coupled receptor 5 (LgR5), and colonic crypt fission. Furthermore, in the azoxymethane mouse model of colorectal carcinogenesis, Cck2r deletion in human progastrin–overexpressing mice resulted in markedly decreased aberrant crypt foci formation and substantially reduced tumor size and multiplicity. Taken together, these observations indicate that progastrin induces proliferative effects, primarily in colonic progenitor cells, through a CCK2R-dependent pathway. Moreover, our data suggest that CCK2R may be a potential target in the treatment or prevention of colorectal cancer.

Authors

Guangchun Jin, Vigneshwaran Ramanathan, Michael Quante, Gwang Ho Baik, Xiangdong Yang, Sophie S.W. Wang, Shuiping Tu, Shanisha A.K. Gordon, David Mark Pritchard, Andrea Varro, Arthur Shulkes, Timothy C. Wang

×

Figure 8

The CCK2R antagonist YM022 blocks progastrin-dependent colonic mucosal proliferation and increases colonic apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
The CCK2R antagonist YM022 blocks progastrin-dependent colonic mucosal p...
(A) Immunohistochemical staining of BrdU-positive cells (upper panels), and DCAMKL1-positive cells (lower panels) after YM022 treatment in 3 groups of mice (original magnification, ×600). The arrows indicate the locations of DCAMKL1-expressing cells. (B and C) Percentage of BrdU-positive cells (B) and DCAMKL1-positive cells (C) were measured under a high-power light microscope in the 3 groups of mice (n = 4/group). (D) Relative numbers of mouse colonic mucosa crypt fissions in each slide section (n = 4/group). (E) Average percentage of TUNEL-positive cells at different locations in the colon in the 3 groups of mice (n = 4/group). All values represent the mean ± SD. *P < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts